Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PHVS Stock Forecast 2026-2027
$31.59
Current Price
$2.21B
Market Cap
Buy 12
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to PHVS Price Targets
+130.3%
To High Target of $72.76
+31.1%
To Median Target of $41.40
+2.8%
To Low Target of $32.49
PHVS Price Momentum
+9.0%
1 Week Change
+5.0%
1 Month Change
+75.2%
1 Year Change
+13.8%
Year-to-Date Change
-5.2%
From 52W High of $33.33
+97.4%
From 52W Low of $16.00
📊 TOP ANALYST CALLS
Did PHVS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Pharvaris is one of their latest high-conviction picks.
Latest PHVS Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, PHVS has a bullish consensus with a median price target of $41.40 (ranging from $32.49 to $72.76). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $31.59, the median forecast implies a 31.1% upside. This outlook is supported by 12 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PHVS Analyst Ratings
12
Buy
1
Hold
0
Sell
PHVS Price Target Range
Low
$32.49
Average
$41.40
High
$72.76
Current: $31.59
Latest PHVS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PHVS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 13, 2026 | Citizens | Jonathan Wolleben | Market Outperform | Maintains | $74.00 |
| Apr 9, 2026 | Wolfe Research | Outperform | Initiates | $N/A | |
| Apr 7, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Apr 6, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| Mar 9, 2026 | RBC Capital | Outperform | Initiates | $N/A | |
| Mar 3, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 4, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Dec 4, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| Dec 4, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Dec 4, 2025 | B of A Securities | Neutral | Maintains | $N/A | |
| Dec 3, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 14, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Nov 13, 2025 | Wedbush | Outperform | Maintains | $N/A | |
| Nov 13, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 15, 2025 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Oct 9, 2025 | B of A Securities | Neutral | Upgrade | $N/A | |
| Aug 13, 2025 | JMP Securities | Market Outperform | Maintains | $N/A | |
| Jun 5, 2025 | Wedbush | Outperform | Reiterates | $N/A | |
| May 14, 2025 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| May 14, 2025 | Wedbush | Outperform | Maintains | $N/A |
Pharvaris N.V. (PHVS) Competitors
The following stocks are similar to Pharvaris based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Pharvaris N.V. (PHVS) Financial Data
Pharvaris N.V. has a market capitalization of $2.21B with a P/E ratio of -10.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -73.0%.
Valuation Metrics
Market Cap
$2.21B
Enterprise Value
$2.06B
P/E Ratio
-10.6x
PEG Ratio
0.4x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+11.9%
Current Ratio
11.2x
Debt/Equity
0.3x
ROE
-73.0%
ROA
-42.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Pharvaris N.V. (PHVS) Business Model
About Pharvaris N.V.
What They Do
Develops therapies for hereditary angioedema.
Business Model
Pharvaris N.V. operates as a biopharmaceutical company focused on discovering and commercializing therapies for hereditary angioedema (HAE) and related diseases. The company generates revenue primarily through the development of innovative oral treatments that serve as alternatives to injectable therapies, thereby addressing unmet medical needs in the market.
Additional Information
Headquartered in Leiden, the Netherlands, Pharvaris is dedicated to enhancing patient quality of life through advanced treatment options for rare genetic conditions. The company plays a vital role in the biotechnology sector, contributing to the evolution of targeted medicinal solutions that meet the growing demand in modern healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
108
CEO
Mr. Berndt Axel Edvard Modig CPA, M.B.A.
Country
Switzerland
IPO Year
2021
Website
pharvaris.comPharvaris N.V. (PHVS) Latest News & Analysis
Latest News
Quick Summary
Pharvaris (Nasdaq: PHVS) announced acceptance of one oral and seven flash talk/poster abstracts for the EAACI Congress, June 12-15, 2026, focusing on treatments for bradykinin-mediated diseases.
Why It Matters
Pharvaris's upcoming presentations at a major medical congress indicate strong potential for investor interest, highlighting its commitment to innovation in treating bradykinin-mediated diseases.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pharvaris expects pivotal Phase 3 data for deucrictibant XR in Q3 2026 and NDA submission for deucrictibant IR in H1 2026. They reported €247M cash and a recent $132M offering, extending runway to 2028.
Why It Matters
Pharvaris's upcoming clinical data and NDA submission timeline signal potential market entry for new treatments, while strong cash reserves indicate financial stability, enhancing growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Pharvaris N.V. (PHVS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
26 days ago
Quick Summary
Pharvaris N.V. (PHVS) presented at the Bank of America Global Healthcare Conference 2026, discussing its developments and strategic initiatives.
Why It Matters
Pharvaris's presentation at a major healthcare conference can signal advancements in their pipeline, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Pharvaris N.V. closed an underwritten offering of 4.46 million shares, raising approximately $132.3 million for its development of bradykinin B2 receptor antagonists for angioedema.
Why It Matters
Pharvaris raised $132.3 million through a share offering, enhancing its financial position for developing treatments for bradykinin-mediated diseases, which could impact future revenue and growth potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pharvaris N.V. (Nasdaq: PHVS) announced a public offering of 3.87 million shares at $29.68 each, aiming for $115 million in gross proceeds. The offering closes around May 11, 2026.
Why It Matters
Pharvaris' $115 million stock offering indicates financial strategy and potential growth, impacting share value and market perception of its drug development prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pharvaris presented safety data for its deucrictibant formulations at the CIIC Spring 2026 Conference, focusing on treatment for bradykinin-mediated diseases like hereditary angioedema.
Why It Matters
Pharvaris's data presentation on deucrictibant's safety could indicate progress in tackling unmet medical needs, potentially influencing stock value and market perception for biopharmaceutical investments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PHVS Stock
What is Pharvaris N.V.'s (PHVS) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Pharvaris N.V. (PHVS) has a median price target of $41.40. The highest price target is $72.76 and the lowest is $32.49.
Is PHVS stock a good investment in 2026?
According to current analyst ratings, PHVS has 12 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $31.59. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PHVS stock?
Wall Street analysts predict PHVS stock could reach $41.40 in the next 12 months. This represents a 31.1% increase from the current price of $31.59. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Pharvaris N.V.'s business model?
Pharvaris N.V. operates as a biopharmaceutical company focused on discovering and commercializing therapies for hereditary angioedema (HAE) and related diseases. The company generates revenue primarily through the development of innovative oral treatments that serve as alternatives to injectable therapies, thereby addressing unmet medical needs in the market.
What is the highest forecasted price for PHVS Pharvaris N.V.?
The highest price target for PHVS is $72.76 from at , which represents a 130.3% increase from the current price of $31.59.
What is the lowest forecasted price for PHVS Pharvaris N.V.?
The lowest price target for PHVS is $32.49 from at , which represents a 2.8% increase from the current price of $31.59.
What is the overall PHVS consensus from analysts for Pharvaris N.V.?
The overall analyst consensus for PHVS is bullish. Out of 8 Wall Street analysts, 12 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $41.40.
How accurate are PHVS stock price projections?
Stock price projections, including those for Pharvaris N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 9, 2026 4:51 AM UTC